Clinical trials: Staphylococcal Sepsis
Nosocomial Neonatal Sepsis
Neonatal Suspected Sepsis Treated With Cefazolin or Vancomycin
The objective is to evaluate the effectiveness of empiric treatment with cefazolin versus to vancomycin in newborn infants with presumptive clinical signs of hospital acquired bacterial sepsis probably caused by…
- Trial name
- NCT01867138
- Testing
- Cefazolin, Vancomycin, Amikacin
- Where
- Argentina
- Volunteers
- 109 people
- Sponsor
- Hospital Italiano de Buenos Aires
Systemic Infection
Pharmacokinetics (PK) of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio)
Multiple center, open-label, PK study
- Trial name
- Staph (NCT01728363)
- Testing
- Antibiotic
- Where
- 10 sites in United States
- Volunteers
- 63 people
- Sponsor
- Phillip Brian Smith
Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
Linezolid Plus Standard of Care
The aim of the study is to assess whether targeting virulence factors by administering linezolid in addition to standard antibiotic treatment improves outcomes in patients with Staphylococcus aureus bacteraemia.
- Trial name
- LIPS (NCT06958835)
- Testing
- Linezolid 600 mg
- Where
- 12 sites in Switzerland
- Volunteers
- 606 people
- Sponsor
- University Hospital, Basel, Switzerland
Neonatal Staphylococcal Sepsis
Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110
"Phase I/II, Randomized, Double Blind, Placebo Controlled, Dose Escalating, Safety and Pharmacokinetics Study in Very Low Birth Weight Neonates of Four Doses of BSYX-A110 for the Prevention of S.
- Trial name
- N002 (NCT00631878)
- Testing
- Pagibaximab (formerly BSYX-A110)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Biosynexus Incorporated
Bacteremia Due to Methicillin Susceptible Staphylococcus Aureus
Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia
"Methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia remains a major cause of community- or hospital-acquired bloodstream infections with an overall mortality estimated around 25%.
- Trial name
- CLOCEBA (NCT03248063)
- Testing
- Cloxacillin, Cefazolin
- Where
- France
- Volunteers
- 315 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Toxic Shock Syndrome Staphylococcal
Phase I STEBVax in Healthy Adults
The main purpose of this study is to test the safety of a new vaccine, STEBVax, which may lead to a useful treatment for toxic shock syndrome.
- Trial name
- NCT00974935
- Testing
- Aluminum hydroxide, STEBVax vaccine
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Bacteremia
Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT)
To assure the uniform collection, handling, storage and transport of patient whole blood specimens and associated information to support validation of the T2 Bacteremia Assay.
- Trial name
- DIREBT (NCT01919762)
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- T2 Biosystems
Immune Response To Sepsis, Staphylococcus Aureus Infection
Immune Resolution After Staphylococcus Aureus Bacteremia
The purpose of this study is to determine how monocyte HLA-DR and other markers of immune function change with time in patients with and without prior immune dysfunction who survive sepsis from Staphylococcus aureus bacteremia.
- Trial name
- NCT01879761
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of Chicago
Bacteremia
Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA
In vitro identification of S. aureus,methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA)from positive blood culture using MicroPhage's bacteriophage-based diagnostic platform.
- Trial name
- NCT01640886
- Where
- 3 sites in United States
- Volunteers
- 764 people
- Sponsor
- MicroPhage, Inc.
Staphylococcal Sepsis
Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis
Evaluate the safety, PK and efficacy comparing Pagibaximab Injection to placebo in preventing staphylococcal sepsis in very low birth weight infants.
- Trial name
- NCT00646399
- Testing
- Pagibaximab 50 mg/mL
- Where
- United States
- Volunteers
- 1,579 people, healthy volunteers welcome
- Sponsor
- Biosynexus Incorporated
Bacteremia
Virulence Determinants in S Aureus Bacteremia
The purpose of this study is to investigate why some people develop life-threatening infections caused by the bacteria Staphylococcus aureus, while other people do not.
- Trial name
- NCT00319826
- Testing
- No intervention
- Where
- United States
- Volunteers
- 1,354 people, healthy volunteers welcome
- Sponsor
- Duke University
Staphylococcus Aureus Bacteremia
Staphylococcus Aureus Bacteraemia (SAB)-Support-Study
The main objective of this study is to investigate whether checklist-based close telephone consultation and process surveillance for S.
- Trial name
- SABOT (NCT06249451)
- Testing
- Checklist-based phone calls
- Where
- Germany
- Volunteers
- 124 people
- Sponsor
- University Medicine Greifswald
Severe Sepsis
Platelet-associated Inflammation in Severe Sepsis
Sepsis represents a serious public health issue characterized by a complex inflammatory response. In addition to their hemostatic role, platelets display inflammatory functions by secreting a variety of immunomodulatory factors…
- Trial name
- PlatISSep (NCT03029039)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Staphylococcus Aureus, Staphylococcal Skin Infections
Rapid Test to Detect Staphylococcus Aureus in Blood and Wound Infections
The purpose of this study is to determine whether the Cepheid GeneXpert system accurately detects Methicillin-Resistant and -Susceptible Staphylococcus aureus in blood cultures and wound swabs.
- Conditions
- Staphylococcus Aureus, Staphylococcal Skin Infections, Bacteremia
- Trial name
- NCT01198262
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Michael E. DeBakey VA Medical Center
Blood Stream Infections, MRSA Infections
Testing Spread and Implementation of Novel Methicillin Resistant Staphylococcal Aureus (MRSA)-Reducing Practices
The purpose of this study is to implement strategies for improved efficiency and waste reduction ("Toyota Lean") and positive deviance, a social behavioral change process, utilizing frontline healthcare personnel to reduce…
- Trial name
- NCT01255943
- Testing
- healthcare staff processes for infection prevention
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- MaineHealth
Bacterial Infections
Clinical Impact of Rapid AST Directly From Blood Cultures
Bacteremia is defined as pathogenic bacteria presence in blood as evidenced by positive blood cultures. These bacteremia have significant consequences in terms of morbidity and mortality (ref. 1,2,3).
- Trial name
- MHR-BC (NCT03992703)
- Where
- France
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Fondation Hôpital Saint-Joseph
Staphylococcal Infections, Bacteremia
A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. Epidermidis
The purpose of this study is to establish the tolerability of treatment with human lactoferrin 1-11 peptide (hLF1-11) administered intravenously as a single dose given for 10 consecutive days, to patients with bacteremia due to…
- Trial name
- LIST (NCT00509847)
- Testing
- human lactoferrin peptide 1-11
- Where
- Netherlands
- Sponsor
- AM-Pharma
Catheter Bacteremia, Staphylococcus Aureus Infection
Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus
The primary objective of the study is to demonstrate, among patients with non-complicated CR-BSIs due to S. aureus, that a single-dose of intravenous (IV) dalbavancin 1500 mg is non-inferior to standard documented antibiotic…
- Trial name
- DALICATH (NCT05117398)
- Testing
- Dalbavancin administration, Standard antibiotic therapy
- Where
- 2 sites in France
- Volunteers
- 406 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Staphylococcus Aureus Bacteremia
Staphylococcus Aureus Bacteraemia in Adults
The purpose of this evaluation is to record the management and outcome of adults with S.aureus bacteraemia (SAB) across multiple European, Asian and North American sites and to identify key quality indicators associated with…
- Trial name
- ISAC (NCT02098850)
- Where
- 24 sites in Germany, South Korea and 3 more
- Volunteers
- 2,000 people
- Sponsor
- University of Cologne
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia
There is a variety of in vitro, in vivo (animal model), and human case series data which suggests that the addition of ertapenem to cefazolin could improve outcomes in methicillin-susceptible S. aureus bacteremia.
- Conditions
- Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia, Staphylococcal Sepsis, Staphylococcus Aureus Endocarditis
- Trial name
- CERT (NCT04886284)
- Testing
- Ertapenem
- Where
- 7 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Todd C. Lee MD MPH FIDSA